14-day Premium Trial Subscription Try For FreeTry Free
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 10, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

Want to Make Money in Biotech? Do This First

06:17am, Friday, 07'th May 2021
Keeping track of upcoming events is important.
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We look at Heron Therapeutics for the first time since it received a CRL from the FDA late last Spring. The shares are up approximately one-third since we recommended to buy in that dip as the company
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
This biotech titan should be a top player on the merger and acquisition scene next year.
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this event..
LNDC earnings call for the period ending May 31, 2020.
The Global Chemotherapy-induced Nausea and Vomiting Drugs Market will grow by $ 525 mn during 2020-2024
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE